LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

5 result(s)
Filter and sort
5 result(s)
Journal Article > CommentarySubscription Only

Revisiting the minimum incubation period of Zaire ebolavirus

Lancet Infect Dis. 18 August 2023; Volume S1473-3099 (Issue 23); 00506-6.; DOI:10.1016/S1473-3099(23)00506-6
Kofman AD, Haberling DL, Mbuyi G, Martel LD, Whitesell AN,  et al.
Lancet Infect Dis. 18 August 2023; Volume S1473-3099 (Issue 23); 00506-6.; DOI:10.1016/S1473-3099(23)00506-6
Journal Article > ResearchFull Text

Ebola Virus Disease in pregnancy: clinical, histopathologic and Immunohistochemical findings

J Infect Dis. 25 May 2016; Volume 215 (Issue 1); 64–69.; DOI:10.1093/infdis/jiw206
Muehlenbachs A, de la Rosa Vazquez O, Bausch DG, Schafer IJ, Paddock C,  et al.
J Infect Dis. 25 May 2016; Volume 215 (Issue 1); 64–69.; DOI:10.1093/infdis/jiw206
Here we describe clinicopathologic features of EVD in pregnancy. One woman infected with Sudan virus in Gulu, Uganda in 2000 had a stillbirth and survived, and another woman with Bundibugyo virus had a livebirth with maternal and infant death in Isiro, the Democratic Republic of the Congo in 2012. Ebolavirus antigen was seen in the syncytiotrophoblast and placental maternal mononuclear cells by immunohistochemistry, and no antigen was seen in fetal placental stromal cells or fetal organs. In the Gulu case, ebolavirus antigen localized to malaria pigment-laden macrophages. These data suggest trophoblast infection may be a mechanism of transplacental ebolavirus transmission.More
Journal Article > ResearchFull Text

Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness, and treatment

J Infect Dis. 15 November 2007; Volume 196 (Issue s2); DOI:10.1086/520543
Colebunders R, Tshomba A, Van Kerkhove MD, Bausch DG, Campbell P,  et al.
J Infect Dis. 15 November 2007; Volume 196 (Issue s2); DOI:10.1086/520543
The objective of the present study was to describe day of onset and duration of symptoms of Marburg hemorrhagic fever (MHF), to summarize the treatments applied, and to assess the quality of clinical documentation. Surveillance and clinical records of 77 patients with MHF cases were reviewed. Initial symptoms included fever, headache, general pain, nausea, vomiting, and anorexia (median day of onset, day 1-2), followed by hemorrhagic manifestations (day 5-8+), and terminal symptoms included confusion, agitation, coma, anuria, and shock. Treatment in isolation wards was acceptable, but the quality of clinical documentation was unsatisfactory. Improved clinical documentation is necessary for a basic evaluation of supportive treatment.More
Journal Article > ReviewFull Text

Clinical Management of Ebola Virus Disease Patients in Low-Resource Settings

Curr Top Microbiol Immunol. 24 June 2017; DOI:10.1007/82_2017_18
Sprecher A, Van Herp M, Rollin PE
Curr Top Microbiol Immunol. 24 June 2017; DOI:10.1007/82_2017_18
Journal Article > ResearchFull Text

Outbreak of Marburg hemorrhagic fever among miners in Kamwenge and Ibanda Districts, Uganda, 2007

J Infect Dis. 1 November 2011; Volume 204 (Issue suppl_3); DOI:10.1093/infdis/jir312
Adjemian J, Farnon EC, Tschioko F, Wamala JF, Byaruhanga E,  et al.
J Infect Dis. 1 November 2011; Volume 204 (Issue suppl_3); DOI:10.1093/infdis/jir312
Marburg hemorrhagic fever was detected among 4 miners in Ibanda District, Uganda, from June through September, 2007. Infection was likely acquired through exposure to bats or bat secretions in a mine in Kamwenge District, Uganda, and possibly human-to-human transmission between some patients. We describe the epidemiologic investigation and the health education response.More